gnbt - momento da verdade
Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data
:)
http://finance.yahoo.com/news/Generex-P ... l?x=0&.v=1
:)
http://finance.yahoo.com/news/Generex-P ... l?x=0&.v=1
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
The 2010 CTRC-AACR San Antonio Breast Cancer Symposium is presented by Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The prestigious event will be held between December 8-12, and brings together the top cancer researchers from around the world.
At this year's event, unexpected new data will be presented from the Phase II study of the AE37 HER2/neu Peptide Vaccine for early stage breast cancer patients will be presented by researchers from the United States Military Cancer Institute. The Phase II study is a prospective, randomized, multi-center clinical trial investigating whether the AE37 Vaccine can prevent recurrence in disease-free, conventionally treated, node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence. Generex is collaborating with the USMCI in this exciting study.
The data is unexpected, since we are currently unaware of any clinical work where the AE37 Vaccine is given to early stage breast cancer patients either sequentially or concurrently with Herceptin. The researchers at the USMCI have been conducting preliminary work to assess any advantage in a combination immunotherapy with Herceptin and HER2/neu peptide-based vaccines (see here). However, these efforts apeared to focus more on the first generation E75 Peptide Vaccine and the second generation AE37 Peptide Vaccine was not mentioned. In previous blogs, I have speculated that Herceptin used with AE37 may make Herceptin more potent. My theory came from reading available abstracts that evaluated the therapeutic role Herceptin has in "modulating the activity of the cellular immune system in patients with breast cancer". I borrowed that quote from a peer review that appeared in the British Journal of Cancer. The report is titled The Effects of Trastuzumab (Herceptin) on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell Axis in Patients with Breast Cancer. The concluding sentence of the report states that "the coadministration of trastuzumab along with therapies that either promote Th17 or reduce Treg cells may be a particular direction, with the aim of ultimately improving the prognosis for patients unresponsive to trastuzumab or other therapies".
We learned from an abstract presented at ASCO 2010 that the AE37 Vaccine is reducing the levels of Treg cells (see here). The conclusion of the abstract stated that the "AE37 + GM-CSF vaccine decreases Tregs during and after completion of vaccination while GM-CSF alone does not alter Treg levels. This suggests that AE37 may allow the immune system to more effectively fight cancer and correlates with an observed decrease in recurrences." I suppose the USMCI also looked at that AE37 data and recognized the potential for combining AE37 either sequentially or concurrently with Herceptin. The title of the unexpected abstract at this year's SABCS Annual Meeting is Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM-CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting. Trastuzumab = Herceptin. Click on the title for the link to view Poster Sessions 2 Treatment and scroll down to "Therapeutic Strategies: Immunotherapy Clinical" and circle December on your GNBT calender. Generex Oncology, aka Antigen Express, is on the cusp of developing a targeted immunotherapeutic vaccine that may revolutionize how cancer is treated in the near future.
At this year's event, unexpected new data will be presented from the Phase II study of the AE37 HER2/neu Peptide Vaccine for early stage breast cancer patients will be presented by researchers from the United States Military Cancer Institute. The Phase II study is a prospective, randomized, multi-center clinical trial investigating whether the AE37 Vaccine can prevent recurrence in disease-free, conventionally treated, node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence. Generex is collaborating with the USMCI in this exciting study.
The data is unexpected, since we are currently unaware of any clinical work where the AE37 Vaccine is given to early stage breast cancer patients either sequentially or concurrently with Herceptin. The researchers at the USMCI have been conducting preliminary work to assess any advantage in a combination immunotherapy with Herceptin and HER2/neu peptide-based vaccines (see here). However, these efforts apeared to focus more on the first generation E75 Peptide Vaccine and the second generation AE37 Peptide Vaccine was not mentioned. In previous blogs, I have speculated that Herceptin used with AE37 may make Herceptin more potent. My theory came from reading available abstracts that evaluated the therapeutic role Herceptin has in "modulating the activity of the cellular immune system in patients with breast cancer". I borrowed that quote from a peer review that appeared in the British Journal of Cancer. The report is titled The Effects of Trastuzumab (Herceptin) on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell Axis in Patients with Breast Cancer. The concluding sentence of the report states that "the coadministration of trastuzumab along with therapies that either promote Th17 or reduce Treg cells may be a particular direction, with the aim of ultimately improving the prognosis for patients unresponsive to trastuzumab or other therapies".
We learned from an abstract presented at ASCO 2010 that the AE37 Vaccine is reducing the levels of Treg cells (see here). The conclusion of the abstract stated that the "AE37 + GM-CSF vaccine decreases Tregs during and after completion of vaccination while GM-CSF alone does not alter Treg levels. This suggests that AE37 may allow the immune system to more effectively fight cancer and correlates with an observed decrease in recurrences." I suppose the USMCI also looked at that AE37 data and recognized the potential for combining AE37 either sequentially or concurrently with Herceptin. The title of the unexpected abstract at this year's SABCS Annual Meeting is Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM-CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting. Trastuzumab = Herceptin. Click on the title for the link to view Poster Sessions 2 Treatment and scroll down to "Therapeutic Strategies: Immunotherapy Clinical" and circle December on your GNBT calender. Generex Oncology, aka Antigen Express, is on the cusp of developing a targeted immunotherapeutic vaccine that may revolutionize how cancer is treated in the near future.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Can you comment on India and how long it will take from this point to commercialize?
Mark: Yes, our product is approved in India. Part of the approval is that a post-approval marketing surveillance study has to be undertaken. Our licensee in India, which is Shreya, is in the process of running that trial, and it has approximately 200 patients in it. I am hopeful that before the end of this year we’ll be able to provide the marketplace with an update on the status of that trial and how long it’s going to take to get commercialization underway in India.
http://investor.generex.com/secfiling.c ... 4-10-56610
Mark: Yes, our product is approved in India. Part of the approval is that a post-approval marketing surveillance study has to be undertaken. Our licensee in India, which is Shreya, is in the process of running that trial, and it has approximately 200 patients in it. I am hopeful that before the end of this year we’ll be able to provide the marketplace with an update on the status of that trial and how long it’s going to take to get commercialization underway in India.
http://investor.generex.com/secfiling.c ... 4-10-56610
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Generex's Antigen Express and France's Stallergenes Co-Author Allergen Research
Scientists from Antigen Express, a wholly owned subsidiary of Generex Biotechnology (GNBT), and France's Stallergenes (GENP.PA) have co-authored a peer review article titled "Researchers Distinct Characteristics of Seasonal Bet v 1 vs. Perennial Der p 1/Der p 2 Allergen-Specific CD4+ T Cell Responses". The article will appear in a future edition of "Clinical & Experimental Allergy" and is available online ahead of print as of November 24th. Stallergenes is a biopharmaceutical company dedicated to immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma.
Stallergenes has been researching the potential of using Ii-Key peptide tetramers as an assay to monitor T cell responses to allergens as part of a collaboration with Antigen Express that was signed in 2005. Since Antigen Express' proprietary Ii-Key peptide hybrids are potent at stimulating CD4+ T cells, in theory they would be useful in detecting the presence of allergen-specific autoimmune T cells in the blood. The CD4+ T cell responses to the Ii-Key assay will evidently help Stallergenes identify which patients would benefit from the specific immunotherapies which they are developing.
The new research article compares the CD4+ T cell responses against seasonal (Bet v 1) and perennial (Der p 1, Der p 2) allergens. Bet v 1 refers to birch pollen allergen while Der p 1, Der p 2 are considered to be the major allergens derived from house dust mites. The researchers inform that "major histocompatibility complex class II peptide tetramers were engineered to monitor allergen-specific T cell responses". A little cheating from Wikipedia tells us that "histocompatibility is the property of having the same, or mostly the same, alleles of a set of genes called the major histocompatibility complex. These genes are expressed in most tissues as antigens, to which the immune system makes antibodies".
The new report from Antigen Express and Stallergenes states that "tetramer+ cells were detected in 19 patients allergic to house dust mites (HDM), seven allergic to birch pollen, 13 allergic to both and nine non-allergics". The report concludes that "different memory CD4+ T cell responses are elicited in the context of chronic vs. seasonal stimulation with the allergen(s). The heterogeneity in the patterns of CD4+ T cell responses observed in patients allergic to HDMs should be taken into account for specific immunotherapy".
A previous peer review published in 2008 by Antigen Express and Stallergenes, titled "Single Cell Assessment of Allergen-Specific T Cell Responses with MHC Class II Peptide Tetramers", revealed that the complex class II peptide tetramers, such as those mentioned in in the new report, were peptides that are "chemically conjugated with the Ii-Key peptide from the MHC invariant chain to facilitate peptide exchange and binding to MHC class II molecules". In the report, the researchers described that the CD4+ T helper cells that are activated to respond to specific allergens can be identified with high sensitivity ex vivo using Ii-Key hybrids. The researchers of the article remarked that Ii-Key peptide tetramers "will also be extremely useful to monitor the efficacy of various immunotherapeutic strategies in humans, using an immunological readout, possibly helping to identify surrogate biological markers of clinical efficacy" and that "Ii-Key conjugate peptides is the most efficient procedure to expand Bet v 1(141-155)-specific CD4+ T cells, allowing to detect such cells in both allergic and healthy individuals".
In April, Stallergenes announced the positive results of a phase III clinical trial conducted in the US for its sublingual grass pollen immunotherapy tablet, Oralair. The Phase III study is the first conducted in the US, after successfully completing four Phase III clinical trials conducted in Europe. Oralair has already been approved by German regulators, and Stallergenes has retained Torreya Partners in hopes of helping them secure a partner for the US market by mid-2011. Stallergenes is currently planning their NDA filing to be submitted to the FDA.
Stallergenes is aware that they also need help in evaluating which patients would most benefit from their allergen immunotherapy tablets, and in their scientific research reports we find evidence that this help may come from an Antigen Express designed assay. Antigen Express' ability to turn their Ii-Key peptide tetramer assay research into a revenue generating asset may not be such a far fetched dream. While that dream remains to be seen, this positive research report concerning Antigen Express' proprietary Ii-Key technology is certainly a step in the right direction.
Scientists from Antigen Express, a wholly owned subsidiary of Generex Biotechnology (GNBT), and France's Stallergenes (GENP.PA) have co-authored a peer review article titled "Researchers Distinct Characteristics of Seasonal Bet v 1 vs. Perennial Der p 1/Der p 2 Allergen-Specific CD4+ T Cell Responses". The article will appear in a future edition of "Clinical & Experimental Allergy" and is available online ahead of print as of November 24th. Stallergenes is a biopharmaceutical company dedicated to immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma.
Stallergenes has been researching the potential of using Ii-Key peptide tetramers as an assay to monitor T cell responses to allergens as part of a collaboration with Antigen Express that was signed in 2005. Since Antigen Express' proprietary Ii-Key peptide hybrids are potent at stimulating CD4+ T cells, in theory they would be useful in detecting the presence of allergen-specific autoimmune T cells in the blood. The CD4+ T cell responses to the Ii-Key assay will evidently help Stallergenes identify which patients would benefit from the specific immunotherapies which they are developing.
The new research article compares the CD4+ T cell responses against seasonal (Bet v 1) and perennial (Der p 1, Der p 2) allergens. Bet v 1 refers to birch pollen allergen while Der p 1, Der p 2 are considered to be the major allergens derived from house dust mites. The researchers inform that "major histocompatibility complex class II peptide tetramers were engineered to monitor allergen-specific T cell responses". A little cheating from Wikipedia tells us that "histocompatibility is the property of having the same, or mostly the same, alleles of a set of genes called the major histocompatibility complex. These genes are expressed in most tissues as antigens, to which the immune system makes antibodies".
The new report from Antigen Express and Stallergenes states that "tetramer+ cells were detected in 19 patients allergic to house dust mites (HDM), seven allergic to birch pollen, 13 allergic to both and nine non-allergics". The report concludes that "different memory CD4+ T cell responses are elicited in the context of chronic vs. seasonal stimulation with the allergen(s). The heterogeneity in the patterns of CD4+ T cell responses observed in patients allergic to HDMs should be taken into account for specific immunotherapy".
A previous peer review published in 2008 by Antigen Express and Stallergenes, titled "Single Cell Assessment of Allergen-Specific T Cell Responses with MHC Class II Peptide Tetramers", revealed that the complex class II peptide tetramers, such as those mentioned in in the new report, were peptides that are "chemically conjugated with the Ii-Key peptide from the MHC invariant chain to facilitate peptide exchange and binding to MHC class II molecules". In the report, the researchers described that the CD4+ T helper cells that are activated to respond to specific allergens can be identified with high sensitivity ex vivo using Ii-Key hybrids. The researchers of the article remarked that Ii-Key peptide tetramers "will also be extremely useful to monitor the efficacy of various immunotherapeutic strategies in humans, using an immunological readout, possibly helping to identify surrogate biological markers of clinical efficacy" and that "Ii-Key conjugate peptides is the most efficient procedure to expand Bet v 1(141-155)-specific CD4+ T cells, allowing to detect such cells in both allergic and healthy individuals".
In April, Stallergenes announced the positive results of a phase III clinical trial conducted in the US for its sublingual grass pollen immunotherapy tablet, Oralair. The Phase III study is the first conducted in the US, after successfully completing four Phase III clinical trials conducted in Europe. Oralair has already been approved by German regulators, and Stallergenes has retained Torreya Partners in hopes of helping them secure a partner for the US market by mid-2011. Stallergenes is currently planning their NDA filing to be submitted to the FDA.
Stallergenes is aware that they also need help in evaluating which patients would most benefit from their allergen immunotherapy tablets, and in their scientific research reports we find evidence that this help may come from an Antigen Express designed assay. Antigen Express' ability to turn their Ii-Key peptide tetramer assay research into a revenue generating asset may not be such a far fetched dream. While that dream remains to be seen, this positive research report concerning Antigen Express' proprietary Ii-Key technology is certainly a step in the right direction.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
rg7803 Escreveu:pedro200 Escreveu:Boas,
atenção à gnbt.
Razões:
- http://www.sabcs.org/
- Resultados do Oral-LYN
- Resultados do AE37
- Phase IV India
- .....
Cumprimentos,
(Longo Gnbt)
(Cotação - 0,30)
pedro, desculpa lá, tira-me uma duvida: em que banco ou corretora é que tens conseguido shortar a GNBT? eu no meu não consigo!
Shortar? Não consigo!
Cumprimentos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
pedro200 Escreveu:Boas,
atenção à gnbt.
Razões:
- http://www.sabcs.org/
- Resultados do Oral-LYN
- Resultados do AE37
- Phase IV India
- .....
Cumprimentos,
(Longo Gnbt)
(Cotação - 0,30)
pedro, desculpa lá, tira-me uma duvida: em que banco ou corretora é que tens conseguido shortar a GNBT? eu no meu não consigo!
“Buy high, sell higher...”.
-
- Mensagens: 4262
- Registado: 1/5/2008 23:09
- Localização: Almada.
uma vez que o banco BEST deixou de negociar a acção porque mudou de indice agora só me deixar fechar a posição 
,obrigadoPeftoulas Escreveu:pedro200 Escreveu:Boas,
atenção à gnbt.
Razões:
- http://www.sabcs.org/
- Resultados do Oral-LYN
- Resultados do AE37
- Phase IV India
- .....
Cumprimentos,
(Longo Gnbt)
(Cotação - 0,30)
E para quando está previsto a saída desses resultados??
(mto mto longo gnbt)
- http://www.sabcs.org/ (8 - 12 Dezembro)- AE37 (Dados muito importante!) - Ver Título da apresentação.
- Resultados Oral Lyn - Devem estar para sair os primeiros resultados relativos a universo de 450 pessoas. A amostra total será de 500. É expectável que para Março os ensaios clínicos estejam terminados. A generex deve estar a divulgar os resultados finais, já com todos os dados agregados, relativos aos 450 pacientes. Com esta amostra, será fácil deduzir os resultados finais do oral-lyn. Lá para Outubro de 2011, a generex deve submeter os resultados à FDA.
- Phase IV India - O Presidente da generex afirmou que até ao final do ano vai fazer um ponto da situação da fase IV na india. Neste momento, sabemos que estão 200 pacientes "enrolados". Não sei se os ensaios já terminaram. Na última sessão publica no nasdaq market fiquei com a impressão que o estudo envolve 200 pacientes. Desta forma, poderemos ter uma supresa positiva brevemente.
Cumprimentos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
pedro200 Escreveu:Boas,
atenção à gnbt.
Razões:
- http://www.sabcs.org/
- Resultados do Oral-LYN
- Resultados do AE37
- Phase IV India
- .....
Cumprimentos,
(Longo Gnbt)
(Cotação - 0,30)
E para quando está previsto a saída desses resultados??
(mto mto longo gnbt
)- Mensagens: 41
- Registado: 18/11/2009 17:58
- Localização: 22
Boas,
atenção à gnbt.
Razões:
- http://www.sabcs.org/
- Resultados do Oral-LYN
- Resultados do AE37
- Phase IV India
- .....
Cumprimentos,
(Longo Gnbt)
(Cotação - 0,30)
atenção à gnbt.
Razões:
- http://www.sabcs.org/
- Resultados do Oral-LYN
- Resultados do AE37
- Phase IV India
- .....
Cumprimentos,
(Longo Gnbt)
(Cotação - 0,30)
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
[quote="nk667"]
***Oral Lyn = $billion market
---late of phase III trial in USA (550 patients trial done, final report will be annouced any time from now)
Correcção - 460 pacientes. O protocolo aprovado pela FDA é de 500 pacientes, com o objectivo de determinar a não inferioridade do oral lyn.
---Indian phase IV trial started at 2007, positive result was reported at 2009. I believe they are waiting USA phase III data too.
(correcção fase IV começou em 2009 na india, após a DGSI condicionar a comercialização do oral lyn à realização de uma fase IV). Por outro lado, o que se passa na india é diferente do que se passa noss EUA. As entidades reguladoras são diferentes.
Brevemente (até ao final do ano), segundo dados avançados pela generex, vai haver um update sobre a situação da fase IV na india. Neste momento tem 200 pacientes em observação. Deve estar a terminar. Após isso, os dados são enviados à DGSI....
---Generex already has a distributor in China, once FDA has green light, China will open their door for Oral Lyn.
Distribuidor na China? Não estou a par desta noticia.
2015 diabetes drug market will reach >$50 billions!!!
Que grande mercado!!! para uma empresa de valor de mercado de poucos milhões....
Dá para a generex e para a MNKD (Decisão da FDA, salvo erro, dia 29 de Dez). A MNKD tem um produto diferente da Generex. O problema é a insulina que vai para os pulmões.... a questão é saber se a FDA vai aceitar este pequeno risco... Se o produto da MNKD for aprovado, o dono da MNKD, o Mann vai ficar bilionário.
Cumprimentos,
(longo na generex)
Cotação actual gnbt : 0,32
***Oral Lyn = $billion market
---late of phase III trial in USA (550 patients trial done, final report will be annouced any time from now)
Correcção - 460 pacientes. O protocolo aprovado pela FDA é de 500 pacientes, com o objectivo de determinar a não inferioridade do oral lyn.
---Indian phase IV trial started at 2007, positive result was reported at 2009. I believe they are waiting USA phase III data too.
(correcção fase IV começou em 2009 na india, após a DGSI condicionar a comercialização do oral lyn à realização de uma fase IV). Por outro lado, o que se passa na india é diferente do que se passa noss EUA. As entidades reguladoras são diferentes.
Brevemente (até ao final do ano), segundo dados avançados pela generex, vai haver um update sobre a situação da fase IV na india. Neste momento tem 200 pacientes em observação. Deve estar a terminar. Após isso, os dados são enviados à DGSI....
---Generex already has a distributor in China, once FDA has green light, China will open their door for Oral Lyn.
Distribuidor na China? Não estou a par desta noticia.
2015 diabetes drug market will reach >$50 billions!!!
Que grande mercado!!! para uma empresa de valor de mercado de poucos milhões....
Dá para a generex e para a MNKD (Decisão da FDA, salvo erro, dia 29 de Dez). A MNKD tem um produto diferente da Generex. O problema é a insulina que vai para os pulmões.... a questão é saber se a FDA vai aceitar este pequeno risco... Se o produto da MNKD for aprovado, o dono da MNKD, o Mann vai ficar bilionário.
Cumprimentos,
(longo na generex)
Cotação actual gnbt : 0,32
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
http://www.globalbusinessinsights.com/co...
1. New drug come to market
2. Old drug left from market
3. Mmarket size, who are dominated
4. China and India are next two potentional countries for diabetes
***Oral Lyn = $billion market
---late of phase III trial in USA (550 patients trial done, final report will be annouced any time from now)
---Indian phase IV trial started at 2007, positive result was reported at 2009. I believe they are waiting USA phase III data too.
---Generex already has a distributor in China, once FDA has green light, China will open their door for Oral Lyn.
2015 diabetes drug market will reach >$50 billions!!!
Summary of the "The Diabetes Market Outlook to 2011" report
Diabetes mellitus is a chronic metabolic disorder that is caused by a failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin; type 1 diabetes occurs most often in children or young adults and accounts for 5-10% of the diagnosed diabetes patient population. Type 2 diabetes, or adult-onset diabetes, accounts for 90–95% of diagnosed diabetes cases worldwide, typically developing in middle-aged adults. There are several risk factors associated with type 2 diabetes including age, obesity, high blood pressure, genetics, level of exercise, and a history of cardiac disease. Type 2 diabetes is more prevalent than type 1 and is growing at a faster rate across the 7 major markets, with a forecast prevalence of 49.2m people in 2011, compared to 39.4m people in 2005. Drivers for increased type 2 prevalence include the aging demographic profile and an increase in obesity. Diabetes is the sixth leading cause of death in the US (based on number of death certificates, NIDDK). The global diabetes market was worth $30.1bn in 2009, which was an 11.5% increase from 2008 sales of $27.3bn. The US has the dominant share in the global diabetes market, with 49.6% of 2005 global sales. The large US market share is mainly due to the large population and the high prevalence of diabetes, the increasing incidence of diabetes associated with Western diets and an aging population. OADs represent 58% of the global diabetes market in 2005, with the remainder of sales being from insulins and analogs (40.1%) and other drugs with 1.9%. However, insulins and analogs have seen the largest sales growth at 17.3% in 2005.
There has been a high level of innovation in drug delivery technology within the diabetes market during 2005-6. Key events include advances in inhaled insulins, funding into insulin pills, patch technology and pain free needles for injection. The top 10 leading antidiabetic brands consist of 6 OADs (Actos, Avandia, Amaryl, Basen, metformin HCl, and Avandamet) and 4 insulins (Lantus, Humalog, NovoLog/NovoRapid and Novolin 70/30/actraphane)and generex oral lyn.
1. New drug come to market
2. Old drug left from market
3. Mmarket size, who are dominated
4. China and India are next two potentional countries for diabetes
***Oral Lyn = $billion market
---late of phase III trial in USA (550 patients trial done, final report will be annouced any time from now)
---Indian phase IV trial started at 2007, positive result was reported at 2009. I believe they are waiting USA phase III data too.
---Generex already has a distributor in China, once FDA has green light, China will open their door for Oral Lyn.
2015 diabetes drug market will reach >$50 billions!!!
Summary of the "The Diabetes Market Outlook to 2011" report
Diabetes mellitus is a chronic metabolic disorder that is caused by a failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin; type 1 diabetes occurs most often in children or young adults and accounts for 5-10% of the diagnosed diabetes patient population. Type 2 diabetes, or adult-onset diabetes, accounts for 90–95% of diagnosed diabetes cases worldwide, typically developing in middle-aged adults. There are several risk factors associated with type 2 diabetes including age, obesity, high blood pressure, genetics, level of exercise, and a history of cardiac disease. Type 2 diabetes is more prevalent than type 1 and is growing at a faster rate across the 7 major markets, with a forecast prevalence of 49.2m people in 2011, compared to 39.4m people in 2005. Drivers for increased type 2 prevalence include the aging demographic profile and an increase in obesity. Diabetes is the sixth leading cause of death in the US (based on number of death certificates, NIDDK). The global diabetes market was worth $30.1bn in 2009, which was an 11.5% increase from 2008 sales of $27.3bn. The US has the dominant share in the global diabetes market, with 49.6% of 2005 global sales. The large US market share is mainly due to the large population and the high prevalence of diabetes, the increasing incidence of diabetes associated with Western diets and an aging population. OADs represent 58% of the global diabetes market in 2005, with the remainder of sales being from insulins and analogs (40.1%) and other drugs with 1.9%. However, insulins and analogs have seen the largest sales growth at 17.3% in 2005.
There has been a high level of innovation in drug delivery technology within the diabetes market during 2005-6. Key events include advances in inhaled insulins, funding into insulin pills, patch technology and pain free needles for injection. The top 10 leading antidiabetic brands consist of 6 OADs (Actos, Avandia, Amaryl, Basen, metformin HCl, and Avandamet) and 4 insulins (Lantus, Humalog, NovoLog/NovoRapid and Novolin 70/30/actraphane)and generex oral lyn.
- Mensagens: 78
- Registado: 3/5/2010 21:32
- Localização: 10
Quem ficou ontem com as calças na mão....pode vender hoje a 0,38!!!
As minhas estao bem guardadas, e como ja disse para mim subir ou descer 50% è me irrelevante quando espero um ganho de 1000%!!!
Mas caso isso nao aconteça nao passa nada...ist only money! coisas piores poderiam aconteçer.
sempre que compro uma Biotech esqueço esse dinheiro, mas vou até ao final, ou os produtos sao aprovados e sou bem sucedido ou nao! Nao me ando a chorar so porque a cotaçao subiu açima do meu preço de compra e nao vendi e depois caiu!
E o mais importante è que cada investidor deve pensar por si proprio, impor-se regras e cumprir essas regras e se algo correr mal assumir as culpas!
Bons negocios
niko
As minhas estao bem guardadas, e como ja disse para mim subir ou descer 50% è me irrelevante quando espero um ganho de 1000%!!!
Mas caso isso nao aconteça nao passa nada...ist only money! coisas piores poderiam aconteçer.
sempre que compro uma Biotech esqueço esse dinheiro, mas vou até ao final, ou os produtos sao aprovados e sou bem sucedido ou nao! Nao me ando a chorar so porque a cotaçao subiu açima do meu preço de compra e nao vendi e depois caiu!
E o mais importante è que cada investidor deve pensar por si proprio, impor-se regras e cumprir essas regras e se algo correr mal assumir as culpas!
Bons negocios
niko
- Mensagens: 78
- Registado: 3/5/2010 21:32
- Localização: 10
pvg80713 Escreveu:Caro Dreck,
a ultima vez que olhei para os cofres da GNBT só havia ordens de compra em lotes de 5k. Portanto e se quer vender imagino que tenha que executar vários negócios. Realmente e embora ainda seja cliente do Best, não o uso faz muito tempo. Mas da ultima vez cada negócio era cobrado extra.
boa sorte
Alguem percebu o porquê dos accionistas terem rejeitado o reverse split e arrastarem a acção para fora do Nasdaq ?
Caro pvg84948378,
A comissão não está dependente da quantidade de negócios efectuada. É completamente independente disso.
A rejeição do R/S deveu-se ao facto de que se fosse concretizado, o potencial de queda seria bastante grande.
Eu não consegui votar, mas caso conseguisse seria também para o não.
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
Drecksack Escreveu:pvg80713 Escreveu:não vão abrir-te uma acção em OTC.
Drecsak, tens que falar com eles e pagar as comissões que são muito mais altas.
Muito mais altas ?
No BEST a comissão nos mercados americanos, quer Nasdaq ou OTC é a mesma.
A única diferença é que no caso do OTC terei que telefonar, e portanto a comissão a aplicar é a de ordem por telefone, que é 2 € mais cara.
Confirmado telefónicamente.
Caro Dreck,
a ultima vez que olhei para os cofres da GNBT só havia ordens de compra em lotes de 5k. Portanto e se quer vender imagino que tenha que executar vários negócios. Realmente e embora ainda seja cliente do Best, não o uso faz muito tempo. Mas da ultima vez cada negócio era cobrado extra.
boa sorte
Alguem percebu o porquê dos accionistas terem rejeitado o reverse split e arrastarem a acção para fora do Nasdaq ?
- Mensagens: 4191
- Registado: 19/4/2005 11:11
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
jcms Escreveu:Peftoulas Escreveu:Alguem sabe pq é que o google finance não disponibliza o titulo?
Para a semana já esta disponivel,demora alguns dias.
Não demora nada.
Está disponível aqui: http://finance.yahoo.com/q?s=GNBT.PK
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
Quem está ligado: